The extinguished BEACON of bardoxolone: Not a monday morning quarterback story

American Journal of Nephrology

Volumn 37, Issue 3, 2013, Pages 208-211

  Tayek, John A ^a   Kalantar Zadeh, Kamyar ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BARDOXOLONE METHYL; CREATININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; END STAGE RENAL DISEASE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; HYPOMAGNESEMIA; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; MEDICATION COMPLIANCE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE SPASM; OBESITY; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS; DIABETIC NEPHROPATHIES; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; OLEANOLIC ACID; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; SPASM; WEIGHT LOSS;

EID: 84874616957     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346950     Document Type: Editorial

References (20)

1. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG: Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
2. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ: Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673.
3. Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar-Zadeh K: Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 2012, E-pub ahead of print.
4. Noori N, Kovesdy CP, Bross R, Lee M, Oreopoulos A, Benner D, Mehrotra R, Kopple JD, Kalantar-Zadeh K: Novel equations to estimate lean body mass in maintenance hemodialysis patients. Am J Kidney Dis 2011; 57: 130-139.
5. Rogacev KS, Bittenbring JT, Fliser D: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1745-1746, author reply 1746-1747.
6. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K: Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005; 29: 1115-1120.
7. Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, Nestel PJ, Masuo K, Sari CI, Chopra R, Mariani JA, Schlaich MP: Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 2011; 29: 553-564.
8. Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM: Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transpl 2010; 21: 898-902.
9. Kalantar-Zadeh K, Amin AN: Toward more accurate detection and risk stratification of chronic kidney disease. JAMA 2012; 307: 1976-1977.
10. Kalantar-Zadeh K, Streja E, Molnar MZ, Lukowsky LR, Krishnan M, Kovesdy CP, Greenland S: Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol 2012; 175: 793-803.
11. Kalantar-Zadeh K, Streja E, Kovesdy CP, Oreopoulos A, Noori N, Jing J, Nissenson AR, Krishnan M, Kopple JD, Mehrotra R, Anker SD: The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85: 991-1001.
12. Ix JH, de Boer IH, Wassel CL, Criqui MH, Shlipak MG, Whooley MA: Urinary creatinine excretion rate and mortality in persons with coronary artery disease: the Heart and Soul Study. Circulation 2010; 121: 1295-1303.
13. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, Luna A, Gomez M, Luna C, Bross R, Nissenson AR, Kalantar-Zadeh K: Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2258-2268.
14. Lee SJ, Johnson JG, Smith CJ, Hatch FE: Renal effects of prostaglandin A1 in patients with essential hypertension. Kidney Int 1972; 1: 254-262.
15. Upadhyay A, Sarnak MJ, Levey AS: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1746, author reply 1746-1747.
16. McMahon GM, Forman JP: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1746, author reply 1746-1747.
17. Van Laecke S, Vanholder R: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1745, author reply 1746-1747.
18. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving H-H, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM: Bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON): rationale and trial design. Am J Nephrol 2013, in press.
19. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG: Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011; 33: 469-476.
20. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.